Biosimilars News

News

Budget Impact Analysis of Biosimilar Bevacizumab for Patients With Cancer

12/09/2021

Study findings indicate that the introduction of biosimilar bevacizumab-bvzr may provide substantial cost savings from the US payers’ perspective, allowing for the bevacizumab treatment to become accessible to more patients.

Study findings indicate that the...

12/09/2021

Journal of Clinical Pathways

News

Obinutuzumab Cost-Effective vs Rituximab Biosimilars for Previously Untreated FL

05/06/2021

For the first-line treatment of FL, obinutuzumab plus chemotherapy is cost-effective in comparison with rituximab biosimilars plus chemotherapy in the United States.

For the first-line treatment of...

05/06/2021

Journal of Clinical Pathways

News

Remaining Challenges, Potential Solutions for the Regulatory Evaluation of Biosimilars

12/16/2020

A recent article outlines challenges that remain regarding the regulatory evaluation of biosimilars and offers potential solutions for the future.

A recent article outlines...

12/16/2020

Journal of Clinical Pathways

News

Policy Review on Improving Oncology Biosimilar Launches

12/11/2020

A recent policy review identifies factors that prevent the effective launch of oncology biosimilars.

A recent policy review...

12/11/2020

Journal of Clinical Pathways

News

Rituximab and Trastuzumab Biosimilars Yield Acceptable Safety in Real-World Setting

10/01/2020

Biosimilar rituximab and biosimilar trastuzumab are associated with acceptable safety profiles among patients with cancer treated in the real-world clinical setting, according to a recent study.

Biosimilar rituximab and...

10/01/2020

Journal of Clinical Pathways

News

ACP Recommendations for Improving Market Competition

09/21/2020

A position paper released by the American College of Physicians made concrete policy reform suggestions for prescription drug competition, calling for a realignment of incentives and rewards for true innovation.

A position paper released by the...

09/21/2020

Journal of Clinical Pathways

News

NCCN, Pfizer Announce Collaboration to Examine Biosimilar Adoption in Oncology

07/29/2020

In a press release published on July 15, 2020, the National Comprehensive Cancer Network (NCCN) Oncology Research Project in collaboration with Pfizer announced an open RFP for projects that support innovative...

In a...

07/29/2020

Journal of Clinical Pathways

News

Pegfilgrastim Biosimilar Increases Value of Cancer Care, Generates Significant Cost-Savings

07/24/2020

Chemotherapy-induced febrile neutropenia prophylaxis with pegfilgrastim-bmez increases the value of cancer care and generates significant cost-savings over the reference product, improving access to care for these...

...

07/24/2020

Journal of Clinical Pathways

News

First-Line Biosimilar-Based Triplet Effective in HER2-Positive Gastric Cancer

07/08/2020

A first-line triplet regimen consisting of pembrolizumab, biosimilar trastuzumab (Herzuma), and chemotherapy is effective in patients with HER2-positive advanced gastric cancer, according to the results of a phase...

A...

07/08/2020

Journal of Clinical Pathways

News

Oncologist Perception of Efficacy, Safety, and Willingness to Prescribe Biosimilars

06/26/2020

Researchers from CVS Health assessed the expected biosimilar prescribing behaviors of practicing oncologists for originator products bevacizumab, trastuzumab, rituximab, and pegfilgrastim. Biosimilars are a...

...

06/26/2020

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Biosimilars News

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products